Supernus Pharmaceuticals (SUPN) EBITDA (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of EBITDA data on file, last reported at -$2.5 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$2.5 million, up 78.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$54.5 million (down 174.68% YoY), and the FY2025 annual result was -$62.3 million, down 176.27% from the prior year.
• EBITDA climbed to -$2.5 million in Q1 2026 per SUPN's latest filing, from -$3.9 million in the prior quarter.
• Over five years, EBITDA peaked at $40.8 million in Q3 2024 and troughed at -$60.2 million in Q3 2025.
• A 5-year average of $3.3 million and a median of $2.0 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 2249.1% in 2024, then sank 274.15% in 2025.
• A 5-year view of EBITDA shows it stood at $34.3 million in 2022, then sank by 102.9% to -$996000.0 in 2023, then jumped by 2249.1% to $21.4 million in 2024, then slumped by 118.39% to -$3.9 million in 2025, then surged by 36.4% to -$2.5 million in 2026.
• Business Quant data shows SUPN's EBITDA at -$2.5 million in Q1 2026, -$3.9 million in Q4 2025, and -$60.2 million in Q3 2025.